The use of Avastin was found helpful, safe, and effective in context of treating a subgroup of recurrent Grade 3 brain tumors as per a subgroup of recurrent Grade 3 brain tumors.

Avastin or Bevacizumab stood out as a potential, effective therapy for gliomas, according to Marc Chamberlain, who is director of the Neuro-oncology Program at the SCCA and a professor of neurology and neurological surgery at the University of Washington School of Medicine and author of the study.

From News-Medical.Net:

Chamberlain said he expects that patients treated with the drug will have a marked improvement in their quality of life because the use of steroids, a common treatment that has significant side effects, can be greatly reduced or even eliminated.

“While treatment with Avastin does dramatically improve survival time, the time that patients have left is of better quality and less about living with the disease itself,” Chamberlain said. In this study, the patients, ages 24-60, received an infusion of bevacizumab every two weeks for an average of 14.5 cycles (range was two to 39 cycles). Fourteen (64 percent) patients showed a partial response to the medicine as shown on radiographic scans. Two patients had stable disease and six had progressive disease. Progression-free survival ranged from three to 18 months and survival for the entire group of patients was three to 19 months.

Avastin is the first-approved therapy for preventing angiogenesis, which is the process wherein important nutrients are transported to a tumor and new blood vessels are developed.